ImmunoGen Inc

Company Profile

ImmunoGen Inc had its IPO on 1990-03-26 under the ticker symbol IMGN.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. ImmunoGen Inc has a staff strength of 0 employees.

Stock update

Shares of ImmunoGen Inc opened at $5.59 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $5.41 - $5.72, and closed at $5.5.

This is a -2.14% slip from the previous day's closing price.

A total volume of 3,315,568 shares were traded at the close of the day’s session.

In the last one week, shares of ImmunoGen Inc have slipped by -8.33%.

ImmunoGen Inc's Key Ratios

ImmunoGen Inc has a market cap of $1.214 billion, indicating a price to book ratio of 5.35 and a price to sales ratio of 13.57.

In the last 12-months ImmunoGen Inc’s revenue was $0.089 billion with a gross profit of $-0.081 billion and an EBITDA of $-0.151 billion. The EBITDA ratio measures ImmunoGen Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, ImmunoGen Inc’s operating margin was -170.7% while its return on assets stood at -26.4% with a return of equity of -101%.

In Q2, ImmunoGen Inc’s quarterly earnings growth was a positive 407.8% while revenue growth was a negative 16.4%.

ImmunoGen Inc’s PE and PEG Ratio

Forward PE

-

Trailing PE

-

PEG

0

Its diluted EPS in the last 12-months stands at $-0.589 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ImmunoGen Inc’s profitability.

ImmunoGen Inc stock is trading at a EV to sales ratio of 10.97 and a EV to EBITDA ratio of -6.47. Its price to sales ratio in the trailing 12-months stood at 13.57.

ImmunoGen Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$0.000 billion

Total Liabilities

$0.000 billion

Operating Cash Flow

$0.000 billion

Capital Expenditure

$0.000 billion

Dividend Payout Ratio

0%

ImmunoGen Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

ImmunoGen Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

ImmunoGen Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, ImmunoGen Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, ImmunoGen Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price

$5.5

52-Week High

$7.77

52-Week Low

$3.1

Analyst Target Price

$11.21

ImmunoGen Inc stock is currently trading at $5.5 per share. It touched a 52-week high of $7.77 and a 52-week low of $7.77. Analysts tracking the stock have a 12-month average target price of $11.21.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.